Survey on the current use of leukapheresis and the collection of granulocyte concentrates

Publisher Website
Google Scholar
Abstract
This study was designed to define leukapheresis practice. A voluntary questionnaire on leukapheresis was sent to 280 FDA[USA Food and Drug Administration]-registered blood-collecting establishments performing leukapheresis. Of the facilities questioned, 67.9% responded. Most facilities use intermittent-flow blood cell separators, while 22.6% use more than 1 separation method. Establishments routinely use 6% hydroxyethyl starch (HES 450/0.70) and the majority use trisodium citrate as the anticoagulant, 48% use corticosteroids, primarily dexamethasone, to pretreat the donor. The frequency of donation was not specified by 25.3% of the report; 42% chose an individual donation frequency of 2 times/wk. A limit on the total number of donations allowed per donor was not specified by 78.4% of the facilities. Community blood banks (including regional centers) performed 55.6% of all leukocyte concentrate collections. The donor reaction incidence was of 3.64%. Hospitals of all types performed 37.8% of the collections. The adverse reaction rate ranged from 2.84-9.72%. Adverse reactions occurred in donors 54.9 times/1000 procedures. Of reported reactions, 94% were mild; moderate and severe reactions accounted for 5.9 and 0.4%, respectively. Granulocyte yields varied by the type of procedure and the use of corticosteroids as well as among facilities. The majority (56.3%) held leukocytes at 22-25.degree. C prior to transfusion, while most of the remainder stored them at 4.degree. C.

This publication has 0 references indexed in Scilit: